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ABSTRACT
The great majority of systemic fungal infections require long-term therapy that often extends 6–12
months, particularly in immunosuppressed patients. It can be difﬁcult to comply with this requirement
when the drug to be used is only available for intravenous administration, because problems related to
maintaining a permeable venous pathway for long periods arise. The availability of an intravenously
(IV) and orally (PO) administered drug can solve this problem by making sequential therapy possible.
Voriconazole is a new antifungal agent that, apart from satisfying this requirement because it has a high
oral bioavailability, presents a broad spectrum of antifungal activity that makes its use possible, a priori,
in the initial and ⁄ or sequential IV ⁄PO treatment of any systemic mycotic infection. Based on current
costs there is potential for savings compared with liposomal amphotericin B.
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INTRODUCTION
Mycosis in general, and systemic mycosis in
particular, present a number of particular features
that differentiate them from any other kind of
infectious process. The incidence when compared
with bacterial or viral infections is clearly lower.
Moreover, mycoses are infectious processes that
usually affect patients with complex conditions in
clinical situations of serious deterioration at a
high iatrogenic risk. Finally, they are infectious
processes that produce high morbidity and mor-
tality despite the use of very aggressive drug
therapy characterised by long duration and the
adverse effects of existing antifungal agents.
Recently, antifungal therapy has been extended
through the introduction of two new drugs,
caspofungin and voriconazole. These can be very
useful in the treatment of some of the more
problematic systemic infections. The latter has a
very interesting feature: the possibility of both
oral and intravenous administration. This is a real
novelty in this group of drugs, at least among
broad-spectrum antifungal drugs.
PATIENTS AND SYSTEMIC MYCOTIC
INFECTION. CONSIDERATIONS ON
THE METHOD OF ADMINISTRATION
OF ANTIFUNGAL DRUGS
As indicated in the introduction, in contrast to
bacterial and viral infections, systemic mycoses
present almost exclusively in certain special types
of patient. The presence of any kind of immuno-
suppression is one of the most important risk
factors; the patient who presents with neutrope-
nia [1,2], who has undergone bone marrow or
solid organ transplantation [3–5], who needs
immunosuppressive therapy for any kind of
disease, who has acquired immune deﬁciency
syndrome (AIDS) with a low CD4 count, or who
is a critically ill patient in an intensive-care
unit [6,7], is therefore part of a group in
which systemic mycotic infections present with
special frequency and virulence because these
processes may be the second and third causes of
infection.
Some of these patients are particularly sus-
ceptible to the presence of maximum levels of
immunosuppression: severe neutropenia, treat-
ment of episodes of acute rejection or graft-
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versus-host disease, etc. In these patients Aspergil-
lus, mucorales and yeasts of the Candida type
appear as particularly prevalent micro-organisms.
For various reasons the critical patient usually
requires broad-spectrum antibiotic therapy which
is considered a major factor in the development of
mycosis, especially those varieties produced by
the selection of Candida-type yeasts in the
patient’s own ﬂora. It is not uncommon for these
patients to receive ﬂuconazole prophylaxis for
deep mycotic infection, and this has been associ-
ated with the selection of some species of yeast
that are particularly resistant to this azole [1,8–14].
An identical situation has been described among
patients with AIDS who have received prophy-
laxis with this drug for oesophageal candidiasis
[15].
The patient with a systemic mycotic infection
therefore presents a disease baseline proﬁle and a
well-deﬁned clinical situation. The requirement
for a permeable central venous access is critical,
either because the patient is not in the right
condition for acceptable oral intake or because
he ⁄ she needs drugs that can only be administered
intravenously. In these circumstances, and at least
initially while oral intake is not possible, antifun-
gal administration for systemic infections is almost
always done intravenously. This can be seen in any
of theprotocols [16–22] that speciﬁcally indicate the
need to administer some intravenous drugs ini-
tially, such as amphotericin Bdeoxycholic, the lipid
forms of the same drug, casponfungin, 5-ﬂuorocy-
tosine, ﬂuconazole, or voriconazole, the latest azole
to be marketed.
In any event, there is a possibility that the
patient presenting a systemic mycotic infection
can also take drugs orally, so this provides the
opportunity to start antifungal therapy using this
route of administration. This should lead us to
consider the risk, albeit theoretical, of the systemic
repercussion of the infection generating problems
that limit the absorption of orally administered
drugs [23,24] and therefore reduce their efﬁcacy.
Although this situation does not always arise, it is
clear that it cannot be deﬁnitively ruled out in
practice. This fact, together with the high mortal-
ity associated with systemic mycosis, means that
attempts should be made to ensure the efﬁcacy of
the therapy, and therefore administer antifungal
drugs intravenously.
The situation can change considerably when a
clear improvement in the infectious condition has
occurred after the ﬁrst few days of intravenous
therapy, and with it the general clinical situation
of the patient. The need to maintain intravenous
therapy thus becomes a continual source of
problems: loss of the pathway with the need to
puncture veins frequently, the presence of effu-
sion or phlebitis (with or without catheter-associ-
ated bacteria), a high risk of infection and ⁄ or
deterioration of the venous reservoir related to
daily use, etc. These situations are always prob-
lematic but are worse in this kind of patient who,
as already indicated, is highly likely to present
severe complications in the face of any of these
intercurrent iatrogenic processes.
This explains why, when the antifungal therapy
lasts longer than 7–10 days, the possibility of
using an orally administered antifungal drug to
replace intravenous therapy becomes a high
priority. This method is currently given the
generic name of ‘sequential therapy’.
Sequential therapy is clearly attractive under
any circumstances. Nevertheless, for it to be
viable one needs to be certain that the change
from intravenous to oral administration does not
lead to a loss of efﬁcacy, either because the
selected drug needs to be absorbed or because a
change of drug involves a reduction in the
intrinsic antifungal activity. In other words, it is
a case of being sure that intravenous to oral
sequential therapy does not mean a risk of
reduced efﬁcacy or, obviously, an increase in
adverse effects.
MYCOTIC INFECTION AND THE
DURATION OF THE THERAPY
A typical feature of the treatment of most sys-
temic fungal infections is that they need long-term
therapy. Table 1 shows the recommended dur-
ation under a range of widely accepted guides
and protocols for the treatment of deep mycoses
of greatest interest. A review of the information
shows that almost all systemic mycotic infections
need antifungal therapy over a very long period
of time. In many situations this includes the need
to administer one of the antifungal drugs intra-
venously on a daily basis for weeks, months, or
even years.
The availability of an antifungal drug that
can be administered orally and demonstrates
appropriate activity may mean that the great
majority of fungal diseases could be treated
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Table 1. Duration of therapy for the main types of mycosis
Infection Medical treatment and duration
Coccidioidomycosis
Diffuse pneumonia [16] Initial therapy with amphotericin B for several weeks. Sequencing to azole
orally when clinical improvement is observed. Total duration of the therapy
is 1 year, although if there is immunosuppression indeﬁnite administration
may be required.
Symptomatic pulmonary nodule,
symptomatic pulmonary cavity [16]
Similar to that of diffuse pneumonia.
Chronic cavitary pneumonia [16] Oral azole for 1 year, if there is no initial response consider amphotericin B IV
Non-meningeal extrapulmonary
localisation [16]
Similar to that of chronic cavitary pneumonia.
Meningitis [25–27] High-dose ﬂuconazole IV ⁄ oral for an indeﬁnite duration. If the clinical
response is not satisfactory, consider intrathecal amphotericin B.
Candidiasis (Rex)
Candidemia and acute disseminated
candidiasis [28]
In a stable patient begin with an azole parenterally, if the patient is unstable
amphotericin B.
Maintain the therapy for 2 weeks after the last positive haemoculture and
all symptoms and signs of the infection have been resolved.
Fever in a neutropenic patient [29–31] Maintain the therapy (amphotericin B or parenteral azole) while the
neutropenia persists.
Hepatosplenic candidiasis [32–34] Maintain prolonged therapy (amphotericin B or parenteral ⁄ oral azole),
probably for several months and, in any event, for the duration
of the chemotherapy.
Neonatal disseminated cutaneous
candidiasis [17]
Amphotericin B or parenteral azole until the complete resolution
of symptoms and signs.
Urinary candidiasis [35] Fluconazole for 7–14 days.
Pneumonia [17] Similar to acute disseminated candidiasis.
Laryngeal form [36,37] Similar to acute disseminated candidiasis.
Osteomyelitis and arthritis [38–40] Amphotericin B for 6–10 weeks or IV ⁄ oral azole for 6–12 months.
Intra-abdominal [41,42] Amphotericin B or parenteral azole. It is usually necessary to maintain the
therapy for at least 2–3 weeks.
Endocarditis [43–45] Amphotericin B with or without ﬂucytosine for at least 6 weeks. If an azole
is used parenterally the therapy should extend for a long period of time.
If valve replacement is not possible indeﬁnite therapy may be required.
Pericarditis, suppurative
phlebitis [46,47]
Amphotericin B or parenteral azole. It is usually necessary to maintain the
therapy for at least 2–3 weeks, although a much longer period may
occasionally be necessary.
Meningitis [48,49] Amphotericin B with ﬂucytosine until the complete resolution of all
symptoms and signs and the normalization of all image and analytical
studies. If an azole is used, IV administration and maintain the therapy
for at least 4 weeks after the resolution of condition.
Endophthalmitis [17] Amphotericin with or without ﬂucytosine and ﬂuconazole can be effective.
The therapy should last from 6 to 12 weeks.
Oesophageal candidiasis [50,51] Oral azole for 2–3 weeks. Amphotericin B if results are ineffective. In patients
with AIDS the indeﬁnite oral administration of ﬂuconazole is effective
in the prevention of episodes.
Blastomycosis [52–56] Amphotericin B total dose of 1.5 g [1 mg ⁄ kg for 3 weeks) or a oral azole for 6
months.
Sporotrichosis Amphotericin B, total dose of 2 g [1 mg ⁄ kg for 4–6 weeks) and ⁄ or itraconazole
for a minimum of 3–6 months.
Pulmonary [57,58] Amphotericin B, total dose of 2 g [1 mg ⁄ kg for 4–6 weeks) and ⁄ or itraconazole
for a minimum of 3–6 months.
Osteoarthritis [57,59] Oral itraconazole for 6–12 months.
Meningitis and disseminated Amphotericin B until the complete resolution of all symptoms and signs.
forms [57,58]
Histoplasmosis Itraconazole for a minimum of 6–12 weeks. If there is intolerance or
ineffectiveness, amphotericin B until the complete resolution of symptoms
and signs.
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sequentially, initiating therapy with the intra-
venous antifungal agent and then continuing
with oral therapy when possible and ⁄ or there is
a clinical improvement. At present only three
antifungal agents can be administered both
orally and intravenously: ﬂucytosine, ﬂuconazole
and voriconazole. The ﬁrst two demonstrate a
moderate level of activity because some frequent
and important fungi, such as Aspergillus, which
are susceptible to these drugs, cannot be inclu-
ded in their spectrum. The third antifungal
agent, voriconazole, has favourable in-vitro activ-
ity against almost all pathogenic fungi (Table 2).
Indeed, one of the most interesting aspects of this
drug is that it is even active against fungi that
are resistant to the other drugs in the same
family.
PHARMACOECONOMIC
CONSIDERATIONS
It is clear that oral therapy for any disease should
mean much lower costs than intravenous therapy.
It may be sufﬁcient to point out the saving
involved in replacing the cost of intravenous
administration, decreasing hospital stay, or elim-
inating the need to visit a day hospital to
administer the drug, plus the cost of some
intravenously administered antifungal agents
and the lipid forms of amphotericin B, to
appreciate the considerable reduction in daily
cost from the moment the change from intraven-
ous to oral administration occurs.
Moreover, it should be noted that therapy
with different forms of amphotericin B has
Table 1. Continued.
Infection Medical treatment and duration
Acute pulmonary [20] Itraconazole for a minimum of 6–12 weeks. If there is intolerance
or ineffectiveness, amphotericin B until the complete resolution
of symptoms and signs.
Chronic pulmonary [60–63] Itraconazole for a minimum of 12–24 months. If there is intolerance or
ineffectiveness, amphotericin B until the complete resolution of symptoms
and signs.
Disseminated [60,64,65] Amphotericin B until the complete resolution of symptoms and signs. If there
is intolerance or ineffectiveness, itraconazole for a minimum of 12–24 months.
Cerebral [66] Amphotericin B total dose of 35 mg ⁄ kg [0.7–1 mg ⁄ kg ⁄day) for 3–4 months.
If there is intolerance or ineffectiveness, ﬂuconazole for a minimum of
9–12 months.
Aspergillosis Amphotericin B or caspofungin or voriconazole until the complete resolution
of symptoms and signs (a minimum of 4–6 weeks). It is recommended to
maintain the therapy in situations where there may be an increase in
immunosuppression. The combination of two of these drugs may be useful.
Invasive pulmonary form [67–70] Amphotericin B or caspofungin or voriconazole until the complete resolution
of symptoms and signs (a minimum of 4–6 weeks). It is recommended
to maintain the therapy in situations where there may be an increase in
immunosuppression. The combination of two of these drugs may be useful.
Cerebral or meningeal [69,71] Amphotericin B and ⁄ or voriconazole IV ⁄ oral.
Cryptococcosis Immunocompetent patient with asymptomatic form: ﬂuconazole
for a minimum of 3–6 months. If the patient presents symptoms of active
infection the therapy is extended between 6 and 12 months. If there is
intolerance or ineffectiveness, or the infection is serious: amphotericin B,
total dose of 1–2 g. Patient with AIDS: maintain the therapy with oral
ﬂuconazole indeﬁnitely.
Pulmonary [72–76] Immunocompetent patient with asymptomatic form: ﬂuconazole for a
minimum of 3–6 months. If the patient presents symptoms of active infection
the therapy is extended between 6 and 12 months. If there is intolerance or
ineffectiveness, or the infection is serious: amphotericin B, total dose of 1–2 g.
Patient with AIDS: maintain the therapy with oral ﬂuconazole indeﬁnitely.
Cerebral [72,74,77–79] Immunocompetent patient: amphotericin B with or without ﬂucytosine
for 6–10 weeks. Once 2 weeks of IV therapy have been completed it
may be useful to replace it with oral ﬂuconazole for 8–10 weeks.
Patient with AIDS: it may be necessary to maintain therapy with oral ﬂuconazole
indeﬁnitely.
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frequently involved some adverse effects on
patients that lead to high costs. Some of these
are related to the need to administer drugs to
avoid the adverse effects. Others involve making
an early diagnosis of the adverse effect (daily
tests) and ﬁnally, the highest costs arise from the
treatment of some of the adverse effects. It is also
necessary to add the costs arising from nonspe-
ciﬁc complications linked to intravenous therapy:
punctured veins, phlebitis, bacteremia, etc.
Nevertheless, the simple addition of the cost of
purchasing the drugs, even without including the
costs indicated above, leads to the conclusion that
the replacement of intravenous therapy by oral
therapy with voriconazole would mean a cost
reduction of such magnitude that it could repre-
sent a daily saving of 400–900 euros (as an
approximate estimation), depending on the dose
of liposomal amphotericin B used. Indeed, the
association of voriconazole and caspofungin rep-
resents a daily cost lower than the maximum dose
of this form of amphotericin B.
ANTIFUNGAL DRUGS, ORAL
ADMINISTRATION AND
SEQUENTIAL THERAPY
The need to avoid long-term intravenous admin-
istration of antifungal agents has been the
reason why itraconazole is used as a sequential
therapy for other intravenous drugs, especially
amphotericin B. This has been possible because
of its availability for oral use in solid form, and
more recently in liquid form. Unfortunately, the
ﬁrst presents a highly variable bioavailability
with a major reduction in bioavailability when
the level of gastric pH rises [98]. Moreover, the
solid form is presented in units of 100 mg, so it
is necessary to administer a large number of
pills every day. Unfortunately, the intravenous
form has not been marketed yet, so intravenous
to oral sequential therapy is not possible with
this drug.
Voriconazole, a recently marketed azole,
offers a number of advantages that make it an
interesting drug for use as a broad-spectrum
antifungal agent in sequential therapy. It has a
broad antifungal spectrum (reviewed in detail in
various sections of this report and referred to in
Table 2). It presents activity against almost all
fungal pathogens at concentrations that are
reached with a conventional dose, regardless of
whether the drug is administered intravenously
or orally. All the reference pathogens that require
long-term treatment are included in its spectrum,
including the most common in our medium such
as yeasts of the Candida type and ﬂuconazole-
resistant varieties.
Table 2. Antifungal activity. CMI90 (mg ⁄L)or range of CMI
Species Fluconazole Itraconazole Voriconazole Ref.
Aspergillus ﬂavus 512 0.125 0.5 [80–84]
Aspergillus fumigatus 512 0.5 0.5 [80–84]
Aspergillus nidulans 256 0.125 0.125 [81,82,84]
Aspergillus niger 256 0.5 0.5 [81–84]
Aspergillus terreus 64 0.125 0.5 [80–82,85,86]
Blastomyces dermatitidis 1–64 0.03–1 0.03–1 [80,87–89]
Candida albicans 2 0.25 0.06 [90–92]
Candida glabrata 64 4 1 [90–92]
Candida guilliermondii 4 1 0.5 [85,92]
Candida krusei 128 2 1 [90–92]
Candida lusitaniae 8 1 0.5 [92,93]
Candida parapsilosis 8 0.5 0.25 [90–92]
Candida tropicalis 1 0.5 0.125 [90–92]
Coccidioides immitis 2–64 0.125–2 0.03–1 [87,89]
Cryptococcus neoformans 16 0.5 0.25 [94–96]
Fusarium solani > 64 > 8 8–16 [80,81,88,93]
Histoplasma capsulatum 0.125–64 0.03–8 0.03–1 [80,87–89]
Malassezia furfur < 0.03–0.03 0.03–0.125 [81,97]
Penicillium marneffei 1–8 0.03–2 0.03–2 [87]
Pracoccidioides brasiliensis 0.125–64 0.03–1 0.03–2 [87]
Pseudallescheria boydii 4–64 1–4 0.06–1 [85]
Sporothrix schenckii 32–128 0.25–4 0.5–6 [80,85,87]
Trichosporon beigelii 0.5–128 0.125–2 0.03–1 [81,85,87]
100 Clinical Microbiology and Infection, Volume 10 Supplement 1, 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 1), 96–106
Regarding the pharmacokinetics, voriconazole
stands out because it presents a very high oral
bioavailability (98.99%), close to 100%. This
drops slightly when it is administered with food
[101], so its administration is recommended at
intervals of approximately 1 hour before or after
food intake. Figure 1 shows a simulation of
plasma concentrations obtained with the pharma-
cokinetic parameters described for the indicated
doses [99]. It shows similar exposures [from the
area under the curve(AUC)] that indicate its high
bioavailability, which is clearly higher than that of
the solid form of itraconazole.
A careful examination of this curve shows that
the maximum plasma concentration stands at
approximately 5 mg ⁄L, even when the drug is
administered intravenously with a dose of
4 mg ⁄kg. This low plasma concentration in rela-
tion to the dosage administered indicates that this
drug is not present in the plasma but has been
distributed quickly and extensively. This is ex-
pressed both by its volume of distribution, which
ranges between 2 and 4.6 L ⁄ kg, and the fact that it
reaches concentrations in tissues that other anti-
fungal drugs ﬁnd hard to access, such as the
cerebrospinal ﬂuid [102–106]. This high distribu-
tion is facilitated by the low percentage of protein
binding (58%).
The elimination of voriconazole is slow, mostly
mediated by CYPP450 isoenzymes 2C19, 2C9 and
to a lesser extent, 3A4 [99,102]. This method of
elimination explains why it is not necessary to
adjust the dose in patients with renal insufﬁ-
ciency, although the accumulation of the intra-
venously administered excipient (cyclodextrine)
means that it is best to avoid the intravenous
administration of voriconazole in patients with
this disease [107]. In patients with hepatic impair-
ment the dose needs to be reduced by half [108].
In children, at the doses studied, the pharmaco-
kinetics were more linear, and it is recommended
to adjust the dose based on weight, independent
of the method of administration [109].
Moreover, like all azoles such as ﬂuconazole
and itraconazole, voriconazole can inhibit the
metabolism of the isozenymes that participate in
its own metabolism, which leads to at least two
consequences: certain risk of interaction [110–120]
and the inhibition of its own metabolism. The
saturation of metabolism is responsible for non-
linear pharmacokinetics, both in the dose and
over time. As a result, dose increases generate
higher concentrations than expected, plus maxi-
mum plasma concentration, and the AUC and the
half-life increases with the multiple dose in
relation to single ﬁrst doses [99].
CYP2C19 is involved in the metabolism of
voriconazole, and it also participates in the
metabolism of ﬂuconazole and itraconazole.
CYP2C19 exhibits genetic polymorphism, and
consequently there may be a part of the Caucasian
(3–5%) and the Asian (15–30%) population that
metabolises these drugs more slowly. Following
the trajectory marked out by its predecessors
within the pharmacological group and as a result
of all these circumstances, this drug presents high
variability in pharmacokinetics. It is therefore
recommended to adjust the dose to weight,
speciﬁcally 4 mg ⁄ kg ⁄ 12 h as a maintenance dose,
at least when the drug is used intravenously.
Voriconazole has been authorized for use as
ﬁrst-line treatment of invasive aspergillosis, seri-
ous infections caused by Candida spp, (including
C. krusei) that are resistant to ﬂuconazole, and also
in serious fungal infections caused by Scedosporium
spp. and Fusarium spp. Its availability on the
market will give rise to real expectations regard-
ing its usefulness in the treatment of other
mycotic infections, where voriconazole will be
used intravenously and orally in sequential
therapy, either with intravenous voriconazole or
with other antifungal drugs such as caspofungin
or amphotericin B, which cannot be adminis-
tered orally. To date, the results of sequential
therapy with this drug have been published or
reported for different indications: fever and neu-
tropenia [121], aspergillosis [103,122–125], infec-
tion by Scedosporium spp. [126,127], infection by
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Fig. 1. Plasma concentrations of voriconazole Oral and IV
(99).
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Pseudallescheria boydii [106], and visceral infections
of different aetiology [128], including those diag-
nosed in children [129].
The experience accumulated over the next few
months and years will determine the usefulness
of this drug, which is highly attractive and an
interesting option for the treatment of systemic
mycotic infections intravenously and ⁄ or orally, at
least in terms of its pharmacological proﬁle.
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